Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTSO Stock Forecast 2025-2026
$0.73
Current Price
$45.85M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CTSO Price Targets
+1,406.8%
To High Target of $11.00
+447.9%
To Median Target of $4.00
+2.7%
To Low Target of $0.75
CTSO Price Momentum
-2.7%
1 Week Change
+2.8%
1 Month Change
-19.8%
1 Year Change
-19.8%
Year-to-Date Change
-54.7%
From 52W High of $1.61
+21.7%
From 52W Low of $0.60
📊 TOP ANALYST CALLS
Did CTSO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CytoSorbents is one of their latest high-conviction picks.
Latest CTSO Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CTSO has a neutral consensus with a median price target of $4.00 (ranging from $0.75 to $11.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.73, the median forecast implies a 447.9% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Sean Lee at HC Wainwright & Co., suggesting a 2.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTSO Analyst Ratings
1
Buy
1
Hold
0
Sell
CTSO Price Target Range
Low
$0.75
Average
$4.00
High
$11.00
Current: $0.73
Latest CTSO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTSO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Nov 14, 2025 | HC Wainwright & Co. | Sean Lee | Neutral | Maintains | $0.75 |
| Sep 16, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Aug 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Aug 8, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Jul 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Jun 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| May 15, 2025 | HC Wainwright & Co. | Sean Lee | Neutral | Reiterates | $1.00 |
| May 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| May 2, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Sean Lee | Neutral | Reiterates | $1.00 |
| Apr 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Feb 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Jan 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Jan 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Nov 12, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Sean Lee | Neutral | Reiterates | $1.00 |
| Nov 8, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $10.00 |
| Nov 4, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $10.00 |
| Oct 22, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $10.00 |
Cytosorbents Corporation (CTSO) Competitors
The following stocks are similar to CytoSorbents based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytosorbents Corporation (CTSO) Financial Data
Cytosorbents Corporation has a market capitalization of $45.85M with a P/E ratio of -1.9x. The company generates $36.98M in trailing twelve-month revenue with a -27.8% profit margin.
Revenue growth is +10.1% quarter-over-quarter, while maintaining an operating margin of -28.1% and return on equity of -93.3%.
Valuation Metrics
Market Cap
$45.85M
Enterprise Value
$65.45M
P/E Ratio
-1.9x
PEG Ratio
-0.1x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
+10.1%
Gross Margin
+70.3%
Operating Margin
-28.1%
Net Margin
-27.8%
EPS Growth
+10.1%
Financial Health
Cash/Price Ratio
+16.4%
Current Ratio
2.1x
Debt/Equity
300.8x
ROE
-93.3%
ROA
-19.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cytosorbents Corporation (CTSO) Business Model
About Cytosorbents Corporation
What They Do
Develops blood purification technologies for critical care.
Business Model
Cytosorbents Corporation generates revenue primarily through the sale of its flagship product, CytoSorb, which is used in hospitals to purify blood by removing harmful inflammatory mediators. The company operates in the healthcare sector, focusing on advanced technologies that enhance treatment outcomes in critical care settings. Additionally, Cytosorbents engages in clinical trials and partnerships to expand its market presence and improve the adoption of its products.
Additional Information
Headquartered in Princeton, New Jersey, Cytosorbents is actively involved in innovative medical solutions aimed at treating severe conditions such as sepsis and trauma. The company is gaining recognition for its contributions to critical care and immunotherapy, positioning itself as a key player in the medical technology landscape.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
149
CEO
Dr. Phillip P. Chan M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.cytosorbents.comCytosorbents Corporation (CTSO) Latest News & Analysis
Latest News
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
21 days ago
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) will present and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference in London from November 17-20, 2025.
Why It Matters
CytoSorbents' participation in the Jefferies Global Healthcare Conference highlights its growth potential and strengthens investor relations, potentially impacting stock performance and market perception.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytosorbents Corporation (CTSO) will hold its Q3 2025 earnings call on November 13, 2025, at 4:30 PM EST, featuring CEO Phillip Chan and CFO Peter Mariani.
Why It Matters
The earnings call provides insights into Cytosorbents' financial performance, strategic direction, and management commentary, which can influence investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CytoSorbents reported Q3 2025 revenue of $9.5M, a 10% increase year-over-year. They amended a credit agreement for an additional $2.5M and extended interest-only periods through mid-2027.
Why It Matters
CytoSorbents' 10% revenue growth and strengthened balance sheet enhance financial stability. FDA progress on DrugSorb-ATR could drive future growth, while cost-cutting measures aim for breakeven by Q1 2026.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) announced leadership updates, including CEO Dr. Phillip Chan and CFO Mr. [name not provided], focusing on blood purification for critical care.
Why It Matters
Leadership changes can signal shifts in company strategy or performance. Investor sentiment may be affected by the new leadership’s vision and ability to drive growth.
Source: PRNewsWire
Market Sentiment:
Neutral
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
1 month ago
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) will announce its Q3 2025 financial results and business updates on November 13, 2025, after market close.
Why It Matters
CytoSorbents' upcoming earnings report may influence stock performance, providing insights into financial health and business progress, crucial for assessing investment potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) honors former Chief Medical Officer Dr. Robert Hawes Bartlett, who passed away at 86. He served from 2008 to 2017.
Why It Matters
The passing of Dr. Bartlett, a key figure in CytoSorbents' development, may impact investor confidence and the company's future direction in medical innovations.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CTSO Stock
What is Cytosorbents Corporation's (CTSO) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Cytosorbents Corporation (CTSO) has a median price target of $4.00. The highest price target is $11.00 and the lowest is $0.75.
Is CTSO stock a good investment in 2026?
According to current analyst ratings, CTSO has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTSO stock?
Wall Street analysts predict CTSO stock could reach $4.00 in the next 12 months. This represents a 447.9% increase from the current price of $0.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cytosorbents Corporation's business model?
Cytosorbents Corporation generates revenue primarily through the sale of its flagship product, CytoSorb, which is used in hospitals to purify blood by removing harmful inflammatory mediators. The company operates in the healthcare sector, focusing on advanced technologies that enhance treatment outcomes in critical care settings. Additionally, Cytosorbents engages in clinical trials and partnerships to expand its market presence and improve the adoption of its products.
What is the highest forecasted price for CTSO Cytosorbents Corporation?
The highest price target for CTSO is $11.00 from at , which represents a 1,406.8% increase from the current price of $0.73.
What is the lowest forecasted price for CTSO Cytosorbents Corporation?
The lowest price target for CTSO is $0.75 from Sean Lee at HC Wainwright & Co., which represents a 2.7% increase from the current price of $0.73.
What is the overall CTSO consensus from analysts for Cytosorbents Corporation?
The overall analyst consensus for CTSO is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are CTSO stock price projections?
Stock price projections, including those for Cytosorbents Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 9:55 AM UTC